RxDoctor Payments Data

Kami Maddocks, MD

Hematology · Columbus, OHNPI 1689698284

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $189,312 of the $236,250 with a category attached, or 80.1%. It is spread thinly across 21 manufacturers, the largest accounting for just 19.0%. Among hematology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$236,250in general payments, 2019–2025

Across 174 payments — averaging $1357.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ADC Therapeutics America, Inc.$45K
  • AbbVie$30K
  • Lilly USA, LLC$26K
  • Bristol Myers Squibb$21K
  • Genentech USA, Inc.$19K
  • Incyte Corporation$15K
  • plus $80K from 15 others
$13,939,489in research payments, 2019–2025

Across 112 payments — averaging $124,460 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pharmacyclics LLC, An Abbvie Company$6M
  • AbbVie$3.9M
  • Acerta Pharma LLC$1.9M
  • Pfizer$1.6M
  • Seagen Inc.$331K
  • ADC Therapeutics America, Inc.$213K
  • plus $52K from 5 others

What the payments were for

  • Consulting fees$189,31280%
  • Speaking & faculty fees$23,58310%
  • Travel & lodging$19,6298%
  • Food & beverage$3,7272%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$236,250 in reported general payments places this provider in the 95th percentile of 84 hematology providers in Ohio.

See all hematology providers in Ohio

Medicare billing

Part B allowed, 2024
$49,290
Medicare patients
202
Services billed
499

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrukinsaZanubrutinib58$795,986
CalquenceAcalabrutinib Maleate46$683,605
ImbruvicaIbrutinib17$277,694
VenclextaVenetoclax14$110,033

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Beigene USA, Inc.Brukinsa$2,275$795,98658 claims
AstraZenecaCalquence$13,865$683,60546 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$3,889$277,69417 claims
AbbVieVenclexta$30,020$110,03314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 84 hematology providers in Ohio.

Other hematology in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →